eyeforpharma Philadelphia 2017: 6 in-depth conferences in one

eyeforpharma20 - 21 April 2017, Philadelphia, USA.
The democratization of healthcare is real, the healthcare delivery landscape is consolidating fast, and the patient is empowered and the customer in charge. Pharma needs to change and develop along with it. 6 in-depth commercial pharma conferences on the key issues of 2017 and beyond, the 6 eyeforpharma Philadelphia 2017 sessions will focus on:

Commercial Leadership

  • Commercial Leadership: Healthcare Leadership: How Pharma Embraces a New Customer Engagement Paradigm
  • Executive Commitment: Recognize Patient Centricity as a Journey: and Spearhead Cultural Change
  • Business Transformation: Your Company Needs to be Disrupted: Corporate Activism for Value Creation
  • Technology Partnerships: Tech meets Pharma: Life Science Partnerships from Bench to Bedside
  • Healthcare Challenges: Approaching the Caregiver Cliff: How Pharma Should Support the Supporters
  • The Implementation Panel: From Words to Action, How to Become a Pharma Intrapreneur

Patients as Partners

  • Patient advocacy 2.0: Manage ‘local customer engagement' from pre to post launch
  • The future of pharma-stakeholder collaboration: Lessons learnt from partnering in the rare disease field
  • Where rubber hits the road: Can patient centricity grow the bottom-line?
  • Case studies on understanding and acting on patient concern

Customer Experience

  • Is the new sales strategy to de-prioritize targets?
  • Customer experience is the key to commercial excellence
  • It's the experience that counts!
  • Look after your customer's journey from start to finish
  • Sales rep 2.0: The new portrait of a customer facing role

Commercial Model Innovation

  • A holistic commercial view: integrate your sales and marketing teams
  • Leverage untapped opportunities with patient-centric selling
  • Customer centricity is key. Are you doing enough?
  • The Modern Marketer: how to stay ahead in a competitive landscape

Pharma's Triple Aim

  • Strengthen the patient ecosystem - improve treatment adherence beyond physician support
  • How to innovate and differentiate your patient assistance solutions
  • Understand factors driving patients' treatment choices
  • Free your engagement from uncertainty around compliance

Digital Transformation

  • Maximize capabilities of your commercial teams with technology
  • Stay ahead of the curve: How digital integration takes your customer’s experience further
  • The power of integrating digital across all aspects of your organization
  • Leveraging Digital: Navigating digital trends and technologies to maximize positive outcomes for patients

Join the most forward thinking speakers from across North America including C-level, VPs and industry leaders from Shire, Otsuka, GSK, Novartis, Pfizer, Google, Sanofi, Takeda and many more. This is the ideal place to ensure your commercial strategy is prepared for 2017 and beyond.

World Pharma News readers can benefit from an exclusive discount - save $200 using our unique discount code WPN200 when you register online.

You can find full details of the meeting here.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

FDA approves first biosimilar for the treatment of…

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvas...

Merck set to join forces with Project Data Sphere …

Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-prof...

FDA approval brings first gene therapy to the Unit…

The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treat...

Novartis appoints Bertrand Bodson as Chief Digital…

Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, rep...

Boehringer Ingelheim Pharmaceuticals, Inc. receive…

Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled sy...

Asthma medicine halves risk of Parkinson's

Parkinson's disease is a chronic disease with unknown causes. The disease destroys the brain cells that control body movements. Shivering, stiff arms and legs and poor co...

This is how belly fat could increase your cancer r…

It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained. A new Mic...

Sanofi and Regeneron announce that cemiplimab (REG…

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemipli...

Tezepelumab significantly reduced asthma exacerbat…

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation ...

Boehringer Ingelheim initiates Phase IIa study of …

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NAS...

Extended treatment with Brilinta reduces risk of c…

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) fro...

Victoza® reduces the risk of major cardiovascular …

A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]